Cell Therapy & Gene Therapy Equipment calculator
Cell Expansion Yield Calculator
Cell Expansion Yield helps manufacturing scientists and process engineers compare final viable cell output with the required target for dosing, cryopreservation, or downstream processing. It is useful during autologous batch review, allogeneic scale-up, and process characterization when expansion performance drives cost and capacity.
What this calculator does
- Calculate harvested viable cell yield against the target cell count for a patient batch, donor lot, or expansion run.
- a manufacturing scientist needs to see whether a cell expansion run produced enough viable cells for the intended dose or lot
- The result shows the percentage of the target viable cell count achieved by the expansion run.
Formula used
- Cell expansion yield = harvested viable cell count ÷ target viable cell count × 100
- Yield gap to minimum target = minimum acceptable expansion yield - cell expansion yield
Inputs explained
- Harvested viable cell count: Use the final viable cell count from the cell counter, flow assay, or batch record after harvest and wash.
- Target viable cell count: Enter the required viable cell count for the patient dose, drug substance lot, cryobag fill, or downstream step.
- Minimum acceptable expansion yield: Use the process target, release criterion, campaign KPI, or internal action limit for expansion yield.
How to use the result
- Use it during batch review, scale-up comparisons, media or cytokine trials, and patient-dose feasibility checks.
- It depends on consistent cell-counting method, dilution, viability gate, sample timing, and whether in-process losses after harvest are included.
Common questions
- What cell count should I enter? Enter viable cells after the same harvest, wash, or concentration step used to judge the batch, not a pre-expansion seed count or total nucleated cell count unless that is your target basis.
- How do I use the yield gap? A positive gap means the run is below the target and may need MSAT review, added expansion time, process changes, or dose allocation decisions.
- Can this compare autologous and allogeneic workflows? Yes, if both use the same viable cell count basis, but autologous patient variability and allogeneic lot pooling should be interpreted separately.
- When is the result only an estimate? It is only as accurate as the cell count, viability method, sampling representativeness, and any corrections for dilution or downstream losses.
Last reviewed 2026-05-12.